1 01/08/2022 31/07/2023 2023-07-31 false false false false false false false true false false true false false false false false true false No description of principal activities is disclosed 2022-08-01 Sage Accounts Production 23.0 - FRS102_2023 xbrli:pure xbrli:shares iso4217:GBP 07317441 2022-08-01 2023-07-31 07317441 2023-07-31 07317441 2022-07-31 07317441 2021-08-01 2022-07-31 07317441 2022-07-31 07317441 2021-07-31 07317441 bus:RegisteredOffice 2022-08-01 2023-07-31 07317441 bus:LeadAgentIfApplicable 2022-08-01 2023-07-31 07317441 bus:Director1 2022-08-01 2023-07-31 07317441 bus:CompanySecretary1 2022-08-01 2023-07-31 07317441 core:WithinOneYear 2023-07-31 07317441 core:WithinOneYear 2022-07-31 07317441 core:ShareCapital 2023-07-31 07317441 core:ShareCapital 2022-07-31 07317441 core:RetainedEarningsAccumulatedLosses 2023-07-31 07317441 core:RetainedEarningsAccumulatedLosses 2022-07-31 07317441 bus:SmallEntities 2022-08-01 2023-07-31 07317441 bus:AuditExemptWithAccountantsReport 2022-08-01 2023-07-31 07317441 bus:SmallCompaniesRegimeForAccounts 2022-08-01 2023-07-31 07317441 bus:PrivateLimitedCompanyLtd 2022-08-01 2023-07-31 07317441 bus:FullAccounts 2022-08-01 2023-07-31 07317441 core:EntitiesControlledByKeyManagementPersonnel 2023-07-31 07317441 core:EntitiesControlledByKeyManagementPersonnel 2022-07-31
Company registration number: 07317441
(England and Wales)
CARDIOCITY LTD
Unaudited filleted financial statements
for the year ended
31 July 2023
CARDIOCITY LTD
Contents
Directors and other information
Accountants report
Statement of financial position
Notes to the financial statements
CARDIOCITY LTD
Directors and other information
Director Dr C Crockford
Secretary Dr C Crockford
Company number 07317441
Registered office Lab 138
9 St. Johns Street
Colchester
Essex
CO2 7NN
Business address Lab 138
9 St. Johns Street
Colchester
Essex
CO2 7NN
Accountants Griffin Chapman
4 & 5 The Cedars, Apex 12
Old Ipswich Road
Colchester
Essex
CO7 7QR
CARDIOCITY LTD
Chartered accountants report to the director on the preparation of the
unaudited statutory financial statements of CARDIOCITY LTD
Year ended 31 July 2023
In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of CARDIOCITY LTD for the year ended 31 July 2023 which comprise the statement of financial position and related notes from the company's accounting records and from information and explanations you have given us.
As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed at http://www.icaew.com /en/members/regulations-standards-and-guidance/.
This report is made solely to the director of CARDIOCITY LTD, as a body, in accordance with the terms of our engagement letter. Our work has been undertaken solely to prepare for your approval the financial statements of CARDIOCITY LTD and state those matters that we have agreed to state to them, as a body, in this report in accordance with ICAEW Technical Release 07/16 AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than CARDIOCITY LTD and its director as a body for our work or for this report.
It is your duty to ensure that CARDIOCITY LTD has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and loss of CARDIOCITY LTD. You consider that CARDIOCITY LTD is exempt from the statutory audit requirement for the year.
We have not been instructed to carry out an audit or a review of the financial statements of CARDIOCITY LTD. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.
Griffin Chapman
Chartered Accountants
4 & 5 The Cedars, Apex 12
Old Ipswich Road
Colchester
Essex
CO7 7QR
3 April 2024
CARDIOCITY LTD
Statement of financial position
31 July 2023
2023 2022
Note £ £ £ £
Current assets
Debtors 5 6,965 9,098
Cash at bank and in hand 6 1,845
_______ _______
6,971 10,943
Creditors: amounts falling due
within one year 6 ( 14,409) ( 15,600)
_______ _______
Net current liabilities ( 7,438) ( 4,657)
_______ _______
Total assets less current liabilities ( 7,438) ( 4,657)
_______ _______
Net liabilities ( 7,438) ( 4,657)
_______ _______
Capital and reserves
Called up share capital 111 111
Profit and loss account ( 7,549) ( 4,768)
_______ _______
Shareholders deficit ( 7,438) ( 4,657)
_______ _______
For the year ending 31 July 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Director's responsibilities:
- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476;
- The director acknowledges their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the statement of income and retained earnings has not been delivered.
These financial statements were approved by the board of directors and authorised for issue on 03 April 2024 , and are signed on behalf of the board by:
Dr C Crockford
Director
Company registration number: 07317441
CARDIOCITY LTD
Notes to the financial statements
Year ended 31 July 2023
1. General information
The company is a private company limited by shares, registered in England and Wales. The address of the registered office is Lab 138, 9 St. Johns Street, Colchester, Essex, CO2 7NN.
2. Statement of compliance
These financial statements have been prepared in compliance with the provisions of FRS 102, Section 1A, 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
3. Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The financial statements are prepared in sterling, which is the functional currency of the entity.
Going concern
The company's accounts have been prepared on a going concern basis notwithstanding the deficit in funds of £7,438, on the understanding that the director will continue to support the company.
Taxation
The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in the statement of comprehensive income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves. In this case, tax is recognised in other comprehensive income or directly in capital and reserves, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.
Financial instruments
A financial asset or a financial liability is recognised only when the company becomes a party to the contractual provisions of the instrument.
Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.
Debt instruments are subsequently measured at amortised cost.
Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately. For all equity instruments regardless of significance, and other financial assets that are individually significant, these are assessed individually for impairment. Other financial assets or either assessed individually or grouped on the basis of similar credit risk characteristics. Any reversals of impairment are recognised in profit or loss immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.
4. Employee numbers
The average number of persons employed by the company during the year amounted to 1 (2022: 1 ).
5. Debtors
2023 2022
£ £
Other debtors 6,965 9,098
_______ _______
6. Creditors: amounts falling due within one year
2023 2022
£ £
Bank loans and overdrafts 9,809 -
Other creditors 4,600 15,600
_______ _______
14,409 15,600
_______ _______
7. Related party transactions
At 31 July 2023 a loan of £ 6,725 (2022: £ 8,858 ) is due to Cardiocity Ltd by a company which is under the control of the director. The loan is interest free and repayable on demand. In addition, at 31 July 2023 a loan of £nil (2022: £ 11,000 ) is due by Cardiocity Ltd to a company which is under the control of the director. The loan is interest free and repayable on demand.